To date, genetic mutations associated with FDA-approved targeted therapy in patients with AML include FLT3-ITD and tyrosine kinase domain mutations as well as IDH1/IDH2 mutations [14, 15]. The gene discussed is FLT3; the disease is acute myeloid leukemia.